Stocktoria
BIOCRYST PHARMACEUTICALS INC BCRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1994-03-04
BIOCRYST PHARMACEUTICALS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% |
| Net margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% |
| Return on assets | 51.3% | -18.1% | -43.8% | -44.9% | -31.3% |
| Return on equity | -221.4% | 18.7% | 49.7% | 83.9% | 172.0% |
| Debt / equity | -0.00× | -0.66× | -0.67× | -0.79× | -2.79× |
| Current ratio | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 |
| Revenue growth | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% |
Source: SEC EDGAR filings · CIK 0000882796 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.